NeuroOne Q3 product revenue rises 16% to $2.0 million; net loss widens
NeuroOne reported fiscal third-quarter 2026 results for the period ended June 30, 2026. Product revenue rose 16% year over year to $2.0 million and product gross margin reached 59.9%, but the net loss widened to $2.0 million from $1.5 million, and cash fell to $2.0 million from $6.6 million at September 30, 2025.
Key points
- Product revenue was $2.0 million, up from $1.7 million in the year-ago quarter.
- Net loss was $2.0 million, or $(0.23) per basic share, versus $1.5 million, or $(0.19) per basic share, a year earlier.
- Product orders were $2.7 million in the quarter, and fiscal 2026 product orders to date total $11.2 million.
- Cash and cash equivalents were $2.0 million as of June 30, 2026, and the company raised $8.4 million gross through its at-the-market program since the start of the fiscal year (through June 30, 2026).
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.